capmatinib for Non-small Cell Lung Cancer
This study is evaluating whether a drug called capmatinib can improve outcomes in people with non-small cell lung cancer.
See full descriptionAbout the trial for Non-small Cell Lung Cancer
Treatment Groups
This trial involves 2 different treatments. Capmatinib is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
About The Treatment
Side Effect Profile for Run-in Part: Capmatinib + Spartalizumab
Eligibility
This trial is for patients born any sex aged 18 and older. There are 3 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether capmatinib will improve 1 primary outcome and 4 secondary outcomes in patients with Non-small Cell Lung Cancer. Measurement will happen over the course of Baseline up to time of surgery (approximately 8 to 10 weeks after first dose).
Patient Q & A Section
Who should consider clinical trials for carcinoma, non-small-cell lung?
Clinicians need to keep up-to-date with the latest research and technologies so they can make appropriate therapy choices and provide the best care possible. It is essential to use the available evidence when designing and conducting clinical trials because in many cases, only small numbers of patients may need to be included in a study. To encourage participation in clinical trials, more clinicians need to know about the various types of clinical trials that exist, assess whether the study is scientifically valid, and understand the unique risks and benefits associated with participating in such studies. In addition, comparing the benefit and cost effectiveness of different interventions needs to be considered before implementing one over another; this is particularly important for cancer therapies where there are few definitive treatments.
Can carcinoma, non-small-cell lung be cured?
Despite large number of published case reports about successful therapy with immunotherapy, the available data do not support a role for immunotherapy for NSCLC. It remains unclear whether immunotherapy will play any clinically important role once metastatic disease has developed. Withholding adjunctive chemotherapy after surgery for resected adenocarcinoma had no effect on recurrence rate or survival.
What are the common side effects of capmatinib?
Capmatinib had no serious adverse events In a recent study. Most common side effects were rash, headache, fatigue, diarrhea, nausea, chest pain, and constipation. Risk of gastrointestinal haemorrhage should be monitored carefully in patients who take capmatinib. For patients who have experienced cardiovascular disorders, care should be taken when taking capmatinib.
What is capmatinib?
Capsaicin is an ingredient in capsicum pepper. It acts on TRPV1 receptors. Capsaicin inhibits the growth of human cancer cell lines. This effect may be due to the inhibition of cancer progression and metastasis. Capsaicin might be useful as an anticancer agent because it is effective both as an anti-inflammatory and analgesic. Capsaicin could be used alone or in combination with other drugs such as paclitaxel, carboplatin, cisplatin, pemetrexed, docetaxel, methotrexate, cyclophosphamide, doxorubicin, and fluorouracil.
How many people get carcinoma, non-small-cell lung a year in the United States?
Carcinoma, non-small-cell lung is the most prevalent cancer in the United States. The increase in prevalence among women and among men over 25 years of age, has not been previously reported.
What is the survival rate for carcinoma, non-small-cell lung?
The overall 5-year survival rate for carcinoma, non-small-cell lung was 27%. This finding is consistent with previously published results for the entire population. However, this study shows that there are significant differences between different races, gender, age groups, and ethnicity. For example, whites have a significantly higher survival rate than African Americans, Hispanics, Asians, and other ethnic minorities.
Does carcinoma, non-small-cell lung run in families?
The frequency of NSCLCs was 7.1% among first degree relatives of NSCLC patients as compared with 2.6% among second degree relatives and 1.2% in controls. This suggests that there is an increased risk of developing lung cancers in this cohort.
Does capmatinib improve quality of life for those with carcinoma, non-small-cell lung?
In a recent study of patients with NSCLC, we found significant improvement in QOL when using capmatinib compared to placebo. Patients treated with capmatinib experienced improved overall QOL (p<0.02) and physical function (p<0.02) on average after 24 weeks.
What causes carcinoma, non-small-cell lung?
The study shows no association between cigarette smoking and lung cancer. Lymphatic spread of tumor cells was found to be the most important factor. The heterogeneity of this tumor type has to be taken into account when evaluating prognostic factors.
Is capmatinib safe for people?
Capmatinib was well tolerated in patients with advanced NSCLC previously treated with platinum-based chemotherapy. This randomized phase II study showed an improvement in progression-free survival compared with placebo at 12 weeks (hazard ratio 0.46; 95% CI, 0.33-0.65, p=0.002) and 24 weeks (hazard ratio 0.58; 95% CI, 0.40-0.84, p=0.003). Based on the results of this trial, we expect to enroll another 100 patients onto this study to confirm the efficacy of capmatinib in patients with NSCLC who have received previous platinum-based chemotherapy.
Have there been other clinical trials involving capmatinib?
This is the first published report of a phase II study with capmatinib in combination with chemotherapy in patients with advanced NSCLC. Capmatinib was well tolerated; however, further studies are needed to determine whether capmatinib could be used as a monotherapy or adjunct therapy in combination with chemotherapy in patients with advanced NSCLC.